190 related articles for article (PubMed ID: 18019690)
21. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
Saif MW; Cornfeld D; Modarresifar H; Ojha B
J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
[TBL] [Abstract][Full Text] [Related]
23. [The usefulness of whole body FDG-PET/CT in patients with brain metastasis].
Nakagawa K; Aoyagi M; Inaji M; Maehara T; Toriyama H; Kawano Y; Tamaki M; Nariai T; Ohno K
No Shinkei Geka; 2009 Feb; 37(2):159-66. PubMed ID: 19227157
[TBL] [Abstract][Full Text] [Related]
24. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy.
Uematsu T; Kasami M; Yuen S
Breast Cancer; 2009; 16(2):97-104. PubMed ID: 18663562
[TBL] [Abstract][Full Text] [Related]
25. Imaging and treatment of patients with colorectal liver metastases in the Netherlands: a survey.
Bipat S; van Leeuwen MS; Ijzermans JN; Bossuyt PM; Greve JW; Stoker J
Neth J Med; 2006 May; 64(5):147-51. PubMed ID: 16702613
[TBL] [Abstract][Full Text] [Related]
26. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
28. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
Fong Y; Saldinger PF; Akhurst T; Macapinlac H; Yeung H; Finn RD; Cohen A; Kemeny N; Blumgart LH; Larson SM
Am J Surg; 1999 Oct; 178(4):282-7. PubMed ID: 10587184
[TBL] [Abstract][Full Text] [Related]
29. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
30. The role of FDG-PET in the selection of patients with colorectal liver metastases.
Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
[TBL] [Abstract][Full Text] [Related]
31. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.
Zubeldia JM; Bednarczyk EM; Baker JG; Nabi HA
Cancer Biother Radiopharm; 2005 Aug; 20(4):450-6. PubMed ID: 16114993
[TBL] [Abstract][Full Text] [Related]
32. Controversies in the management of colorectal liver metastases: role of PET and PET/CT.
Wiering B; Vogel WV; Ruers TJ; Oyen WJ
Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic values of measuring the liver volume in detecting occult hepatic metastases from colorectal cancer.
Ishizawa T; Yamamoto T; Sekikawa T
Hepatogastroenterology; 2007 Mar; 54(74):514-7. PubMed ID: 17523310
[TBL] [Abstract][Full Text] [Related]
34. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
[TBL] [Abstract][Full Text] [Related]
35. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
Strasberg SM; Dehdashti F
J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
[TBL] [Abstract][Full Text] [Related]
36. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
[TBL] [Abstract][Full Text] [Related]
37. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ
ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564
[TBL] [Abstract][Full Text] [Related]
38. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
39. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings.
Lubezky N; Metser U; Geva R; Nakache R; Shmueli E; Klausner JM; Even-Sapir E; Figer A; Ben-Haim M
J Gastrointest Surg; 2007 Apr; 11(4):472-8. PubMed ID: 17436132
[TBL] [Abstract][Full Text] [Related]
40. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.
Boykin KN; Zibari GB; Lilien DL; McMillan RW; Aultman DF; McDonald JC
Am Surg; 1999 Dec; 65(12):1183-5. PubMed ID: 10597072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
